<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin Med J (Engl)</journal-id><journal-id journal-id-type="iso-abbrev">Chin. Med. J</journal-id><journal-id journal-id-type="publisher-id">CMJ</journal-id><journal-title-group><journal-title>Chinese Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0366-6999</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26063354</article-id><article-id pub-id-type="pmc">4733750</article-id><article-id pub-id-type="publisher-id">CMJ-128-1563</article-id><article-id pub-id-type="doi">10.4103/0366-6999.158285</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yue-Xin</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Wen-Da</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Xiao-Jun</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Yong-Quan</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Hong-Yan</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>He-Jie</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Ji-Chun</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xiao-Qiang</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Chang-Wei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100068, China</aff><aff id="aff2"><label>2</label>Department of Vascular Surgery, Peking XuanWu Hospital, Beijing 100053, China</aff><aff id="aff3"><label>3</label>Department of Vascular Surgery, The First Affiliated Hospital of Xi&#x02019;an Jiaotong University, Xi&#x02019;an, Shaanxi 710061, China</aff><aff id="aff4"><label>4</label>Department of Vascular Surgery, Anhui Provincial Hospital, Hefei, Anhui 230001, China</aff><aff id="aff5"><label>5</label>Department of Vascular Surgery, West China Hospital, Chengdu, Sichuan 510100, China</aff><aff id="aff6"><label>6</label>Department of Vascular Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Prof. Chang-Wei Liu, Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100068, China E-Mail: <email xlink:href="liucw@vip.sina.com">liucw@vip.sina.com</email></corresp></author-notes><pub-date pub-type="ppub"><day>20</day><month>6</month><year>2015</year></pub-date><volume>128</volume><issue>12</issue><fpage>1563</fpage><lpage>1566</lpage><history><date date-type="received"><day>09</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2015 Chinese Medical Journal</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Sarpogrelate is a selective 5-hydroxytryptamine (5-HT) receptor subtype 2A antagonist which blocks 5-HT induced platelet aggregation and proliferation of vascular smooth muscle cells. We compared the efficacy of sarpogrelate-based dual antiplatelet therapies for the prevention of restenosis and target lesion revascularization (TLR) rates comparing with that of clopidogrel after percutaneous endovascular interventions (EVIs) of femoropopliteal (FP) arterial lesions.</p></sec><sec id="st2"><title>Methods:</title><p>This prospective, multicenter, randomized clinical trial recruited a total of 120 patients with successful EVI of FP lesions at seven centers across China between January 2011 and June 2012. Patients were randomized to receive either sarpogrelate (100 mg trice daily for 6 months, <italic>n</italic> = 63) or clopidogrel (75 mg once daily for 6 months, <italic>n</italic> = 57). All patients also received oral aspirin (100 mg once daily for 12 months). Clinical follow-up was conducted up to 12 months postprocedure.</p></sec><sec id="st3"><title>Results:</title><p>There was no significant difference between the two groups in basic demographic data. The restenosis rate was higher in the clopidogrel group (22.80%) than in sarpogrelate group (17.50%), but there was no significant difference between these two groups (<italic>P</italic> = 0.465). The TLR rate, ipsilateral amputation rate, mortality in all-cause and bleeding rate were also similar in the two groups (<italic>P</italic> &#x0003e; 0.05).</p></sec><sec id="st4"><title>Conclusions:</title><p>Aspirin plus sarpogrelate is a comparable antithrombotic regimen to aspirin plus clopidogrel after EVI of FP arterial lesions. Dual antiplatelet therapies might play an important role in preventing restenosis after successful EVI of FP lesions.</p></sec></abstract><kwd-group><kwd>Clopidogrel</kwd><kwd>Femoropopliteal Artery</kwd><kwd>Percutaneous Endovascular Interventions</kwd><kwd>Restenosis</kwd><kwd>Sarpogrelate</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>I<sc>NTRODUCTION</sc></title><p>Percutaneous endovascular interventions (EVIs) are widely used to treat patients with femoropopliteal (FP) arterial stenosis or occlusions. Despite the recent development of endovascular therapy, a high incidence of late restenosis through intima hyperplasia remains as a major unsolved problem. The incidence of restenosis is still as high as 39.0%&#x02013;74.3%.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>] For patients undergoing lower extremity balloon angioplasty with stenting, there is a general consensus for long-term use of aspirin (75&#x02013;100 mg/d).[<xref rid="ref4" ref-type="bibr">4</xref>] Still, in the absence of sufficient data, dual antiplatelet therapy is a common clinical practice for lower extremity balloon angioplasty and stenting.</p><p>Sarpogrelate is a newly developed selective 5-hydroxytryptamine receptor subtype 2A (5-HT<sub>2A</sub>) antagonist. It blocks 5-HT induced platelet aggregation. Furthermore, sarpogrelate inhibits 5-HT-induced proliferation of smooth muscle cells in animal models.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] This leads to the suggestion that sarpogrelate is a candidate for inhibiting 5-HT-induced neointimal hyperplasia (restenosis) after angioplasty.[<xref rid="ref8" ref-type="bibr">8</xref>] Fujita <italic>et al</italic>.[<xref rid="ref9" ref-type="bibr">9</xref>] reported that sarpogrelate reduces restenosis after coronary stenting. However, effects of sarpogrelate on restenosis have not been studied in randomized controlled trials of EVIs in the peripheral circulation.</p><p>Based on these results, this prospective, randomized, open-label clinical trial is going to evaluate the effects of sarpogrelate versus clopidogrel based dual antiplatelet therapies in FP arterial EVIs.</p></sec><sec sec-type="methods" id="sec1-2"><title>M<sc>ETHODS</sc></title><sec id="sec2-1"><title>Study design and patient selection</title><p>The study was a prospective, multicenter, randomized, open-label clinical trial. Its protocol was approved by the institutional review board of each center. All patients gave written informed consent.</p><p>A total of 120 patients at seven centers across China were recruited between January 2011 and June 2012 according to the inclusion criteria and exclusion criteria as bellows [<xref ref-type="table" rid="T1">Table 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Inclusion criteria and exclusion criteria</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">Inclusion criteria</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Patient inclusion criteria</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Adult patients above 18 years old who underwent successful angioplasty (PTA) with or without stents for FP arterial lesions</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Successful PTA was defined as diameter stenosis &#x0003c;30% with the relief of symptoms</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Be able to be followed up for at least 6 months after surgery</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lesion inclusion criteria</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Angiographically-confirmed significant FP artery stenosis or occlusions caused by the arteriosclerosis disease</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;At least 1 arterial runoff BTK, but stenosis lesions not limiting flow may be included</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Without residual inflow problems in aortoiliac artery, but stenosis lesions not limiting flow may be included</td></tr><tr><td align="left" rowspan="1" colspan="1">Exclusion criteria</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Patient exclusion criteria</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Patients with or at risk of hemorrhagic complications or bleeding tendency</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Patients with acute lower limb ischemia</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Patients with thrombophilia</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Patients with known contraindications for aspirin, clopidogrel, sarpogrelate or contrast agents</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Allergic to aspirin, clopidogrel, sarpogrelate, contrast agents or other NSAID</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;Hemophilia</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;Thrombocytopenia</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;Severe hepatic dysfunction</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;Pregnancy or lactation</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;Severe renal dysfunction</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Patients have to use warfarin</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Previous bypass surgery or angioplasty for the FP lesions</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lesions exclusion criteria</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Remnant inflow problems</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;No arterial runoff BTK</td></tr></tbody></table><table-wrap-foot><fn><p>PTA: Percutaneous transluminal angioplasty; FP: Femoropopliteal; BTK: Below the knee; NSAID: Nonsteroidal anti-inflammatory drug.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-2"><title>Procedure and randomization</title><p>Prior to percutaneous EVI, all patients received oral aspirin (100 mg/d) for at least 1-week. When intervention, percutaneous transluminal angioplasty (PTA) for FP lesions was performed either by antegrade approach or crossover through the bifurcation approach. Unfractionated heparin (100 units/kg) was allowed to use during the procedure. The lesion was expanded using an optimal balloon for 60 s. Bare-metal self-expanding stents were implanted in accordance with the American College of Cardiology/American Heart Association guidelines in patients presenting with a residual pressure gradient &#x0003e;10 mmHg, residual stenosis &#x0003e;30%, or flow-limiting dissection after balloon dilatation.</p><p>After successful EVI, eligible patients were randomized to sarpogrelate group or clopidogrel group. Randomization was performed with the use of computer-generated random digits, and the assignments were placed in sealed envelopes. To ensure an equal distribution of treatment regimen in each center, block random design was applied. From surgery to postoperative 6 months, the patients in sarpogrelate group receive sarpogrelate (100 mg tid) plus aspirin (100 mg/day), and the patients in clopidogrel group receive clopidogrel (75 mg/day) plus aspirin (100 mg/day). Sarpogrelate or clopidogrel was started from successful surgery and continued until 6 months only if there are severe complications requiring discontinuance of these drugs. Aspirin overlapped the whole 12 months. Angiotensin converting enzyme inhibitor, b-blocker, statins, and calcium-channel blocker were allowed for patients when indicated. However, other antiplatelet agents were not allowed for study patients.</p></sec><sec id="sec2-3"><title>Follow-up</title><p>Telephone follow-ups were conducted at 1, 2, 4, 5 months after PTA. Telephone follow-ups included clinical symptoms according to Fontaine/Rutherford classification criteria. Visit follow-ups were conducted at 3, 6, 12 months after PTA in the outpatient clinic by the study investigator. Visit follow-up examinations included clinical symptoms according to Fontaine/Rutherford classification criteria, ankle brachial pressure index (ABI), and Doppler ultrasound scanning. Unscheduled follow-ups included clinical symptoms according to Fontaine/Rutherford classification criteria, ABI and other necessary examinations. If patients had worsened clinical symptoms, lowered ABI by 0.2 or abnormal Doppler ultrasound, arteriography had to be performed. If patients were not eventful, arteriography was required at 12 months follow-up. All causes of death, amputation, bleeding complication, and the need of target lesion revascularization (TLR) were recorded.</p><p>Other characters required included age, sex, pre-PTA Fontaine/Rutherford classifications, Transatlantic Inter-Society Consensus (TASC) classification for FP lesions by angiography, comorbidities (hypertension, hypercholesterolemia, diabetes mellitus, and current smoking), combined medicine therapy, types of stents used, complications and managements.</p></sec><sec id="sec2-4"><title>Endpoints</title><p>The primary endpoint of the trial was the restenosis and TLR up to 12 months after FP arterial EVI. Restenosis was defined as angiographic luminal diameter stenosis &#x0003e;50%. TLR was defined as repeated PTA in patients who had a restenosis. The secondary endpoints were ipsilateral amputation due to lower extremity ischemia, mortality by all causes and bleeding complications.</p></sec><sec id="sec2-5"><title>Statistics analysis</title><p>All analyses were conducted by the SPSS 19.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were expressed as means &#x000b1; standard division (SD), and categorical variables were presented as counts and percentages. For the analysis of continuous data, unpaired Student's <italic>t</italic>-test and nonparametric analysis by the Mann&#x02013;Whitney U-test were used to assess differences between the two treatment groups. As for categorical data, &#x003c7;<sup>2</sup> test (Pearson Chi-square) and Fisher's exact test were used. The incidence of TLR per patient was analyzed by means of Kaplan&#x02013;Meier survival curves with differences between the two treatment groups compared by Log&#x02013;rank test. Differences were considered statistically significant at a value of <italic>P</italic> &#x0003c; 0.05.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>R<sc>ESULTS</sc></title><sec id="sec2-6"><title>Patient characteristics</title><p>After successful EVI of femoropopliteal arterial lesions, a total of 120 patients were included according to the inclusion criteria and exclusion criteria and randomly assigned to either sarpogrelate group (<italic>n</italic> = 63) or clopidogrel group (<italic>n</italic> = 57) between January 2011 and June 2012. The general demographic data of these patients are listed in <xref ref-type="table" rid="T2">Table 2</xref>. There is no significant difference between the two groups, including age, sex, risk factors, blood tests before EVI, ABI before EVI, Rutherford, and TASC classification, etc. After successful EVI, the ABI was significantly improved (<italic>P</italic> = 0.022).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Basic characteristics of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" valign="top" colspan="1">Characteristics</th><th align="center" colspan="2" rowspan="1">Treatment groups</th><th align="center" rowspan="2" colspan="1"><italic>P</italic></th></tr><tr><th align="left" colspan="2" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Sarpogrelate group (<italic>n</italic> = 63)</th><th align="center" rowspan="1" colspan="1">Clopidogrel group (<italic>n</italic> = 57)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Male (<italic>n</italic>, %)</td><td align="center" rowspan="1" colspan="1">42 (66.67)</td><td align="center" rowspan="1" colspan="1">35 (61.40)</td><td align="center" rowspan="1" colspan="1">0.548</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (mean &#x000b1; SD)</td><td align="center" rowspan="1" colspan="1">68.84 &#x000b1; 9.56</td><td align="center" rowspan="1" colspan="1">69.51 &#x000b1; 9.66</td><td align="center" rowspan="1" colspan="1">0.705</td></tr><tr><td align="left" rowspan="1" colspan="1">Risk factors (<italic>n</italic>, %)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hypertension</td><td align="center" rowspan="1" colspan="1">51 (80.95)</td><td align="center" rowspan="1" colspan="1">40 (70.18)</td><td align="center" rowspan="1" colspan="1">0.168</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hyperlipidemia</td><td align="center" rowspan="1" colspan="1">22 (34.92)</td><td align="center" rowspan="1" colspan="1">16 (28.07)</td><td align="center" rowspan="1" colspan="1">0.420</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Diabetes</td><td align="center" rowspan="1" colspan="1">37 (58.73)</td><td align="center" rowspan="1" colspan="1">36 (63.16)</td><td align="center" rowspan="1" colspan="1">0.483</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Smoke</td><td align="center" rowspan="1" colspan="1">28 (44.44)</td><td align="center" rowspan="1" colspan="1">24 (42.11)</td><td align="center" rowspan="1" colspan="1">0.796</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood tests (mean &#x000b1; SD)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PLT (&#x000d7;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">193.18 &#x000b1; 95.86</td><td align="center" rowspan="1" colspan="1">232.67 &#x000b1; 105.74</td><td align="center" rowspan="1" colspan="1">0.052</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hgb (g/L)</td><td align="center" rowspan="1" colspan="1">125.81 &#x000b1; 19.174</td><td align="center" rowspan="1" colspan="1">132.51 &#x000b1; 40.69</td><td align="center" rowspan="1" colspan="1">0.264</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ALT (U/L)</td><td align="center" rowspan="1" colspan="1">21.68 &#x000b1; 10.37</td><td align="center" rowspan="1" colspan="1">26.91 &#x000b1; 25.32</td><td align="center" rowspan="1" colspan="1">0.154</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;AST (U/L)</td><td align="center" rowspan="1" colspan="1">23.46 &#x000b1; 13.53</td><td align="center" rowspan="1" colspan="1">23.90 &#x000b1; 15.65</td><td align="center" rowspan="1" colspan="1">0.879</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cr (&#x003bc;mol/L)</td><td align="center" rowspan="1" colspan="1">82.24 &#x000b1; 137.08</td><td align="center" rowspan="1" colspan="1">72.99 &#x000b1; 25.91</td><td align="center" rowspan="1" colspan="1">0.643</td></tr><tr><td align="left" rowspan="1" colspan="1">Rutherford</td><td align="center" rowspan="1" colspan="1">60.96</td><td align="center" rowspan="1" colspan="1">54.88</td><td align="center" rowspan="1" colspan="1">0.311*</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;classification (mean rank)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TASC classification</td><td align="center" rowspan="1" colspan="1">35.15</td><td align="center" rowspan="1" colspan="1">39.24</td><td align="center" rowspan="1" colspan="1">0.382*</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;(mean rank)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ABI before EVI (mean &#x000b1; SD)</td><td align="center" rowspan="1" colspan="1">0.43 &#x000b1; 0.26</td><td align="center" rowspan="1" colspan="1">0.43 &#x000b1; 0.19</td><td align="center" rowspan="1" colspan="1">0.978</td></tr><tr><td align="left" rowspan="1" colspan="1">ABI after EVI (mean &#x000b1; SD)</td><td align="center" rowspan="1" colspan="1">0.78 &#x000b1; 0.21</td><td align="center" rowspan="1" colspan="1">0.77 &#x000b1; 0.23</td><td align="center" rowspan="1" colspan="1">0.864</td></tr><tr><td align="left" rowspan="1" colspan="1">Stent numbers (mean &#x000b1; SD)</td><td align="center" rowspan="1" colspan="1">1.61 &#x000b1; 093</td><td align="center" rowspan="1" colspan="1">1.52 &#x000b1; 0.90</td><td align="center" rowspan="1" colspan="1">0.631</td></tr></tbody></table><table-wrap-foot><fn><p>*Nonparametric&#x02019; Mann&#x02013;Whitney test for two independent samples. SD: Standard deviation; PLT: Platelet; Hgb: Hemoglobin; AST: Aspartate aminotransferase; ALT: Alanine transaminase; TASC: Transatlantic Inter-Society Consensus; ABI: Ankle brachial pressure index; EVI: Endovascular intervention.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-7"><title>Clinical follow-up</title><p>Clinical follow-up was available in 100% of the patients. In the whole 120 cases, the 3 months, 6 months, and 12 months restenosis rates were 2.50%, 10.83%, and 20.00% individually. The primary and secondary endpoints are described in <xref ref-type="table" rid="T3">Table 3</xref>. The restenosis rate was higher in the clopidogrel group (22.80%) than in sarpogrelate group (17.50%), but there was no significant difference between these two groups (<italic>P</italic> = 0.465). Kaplan&#x02013;Meier survival curves for patients with restenosis in both groups were shown in <xref ref-type="fig" rid="F1">Figure 1</xref>, and Log&#x02013;rank test indicated that the rates of target lesion restenosis had no statistical significant differences between the sarpogrelate group and clopidogrel group (<italic>P</italic> = 0.507).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Primary and secondary endpoints of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="2" valign="top" colspan="1">Endpoints</th><th align="center" colspan="3" rowspan="1">Treatment groups, <italic>n</italic> (%)</th><th align="center" rowspan="2" colspan="1"><italic>P</italic></th></tr><tr><th align="left" colspan="3" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Total (<italic>n</italic> = 120)</th><th align="center" rowspan="1" colspan="1">Sarpogrelate group (<italic>n</italic> = 63)</th><th align="center" rowspan="1" colspan="1">Clopidogrel group (<italic>n</italic> = 57)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Primary endpoints</td><td align="center" rowspan="1" colspan="1">24 (20.00)</td><td align="center" rowspan="1" colspan="1">11 (17.50)</td><td align="center" rowspan="1" colspan="1">13 (22.80)</td><td align="center" rowspan="1" colspan="1">0.465</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Restenosis</td><td align="center" rowspan="1" colspan="1">24 (20.00)</td><td align="center" rowspan="1" colspan="1">11 (17.50)</td><td align="center" rowspan="1" colspan="1">13 (22.80)</td><td align="center" rowspan="1" colspan="1">0.465</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TLR</td><td align="center" rowspan="1" colspan="1">6 (5.00)</td><td align="center" rowspan="1" colspan="1">4 (6.30)</td><td align="center" rowspan="1" colspan="1">2 (3.50)</td><td align="center" rowspan="1" colspan="1">0.682*</td></tr><tr><td align="left" rowspan="1" colspan="1">Secondary endpoints</td><td align="center" rowspan="1" colspan="1">7 (5.80)</td><td align="center" rowspan="1" colspan="1">3 (4.80)</td><td align="center" rowspan="1" colspan="1">4 (7.0)</td><td align="center" rowspan="1" colspan="1">0.707*</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Ipsilateral</td><td align="center" rowspan="1" colspan="1">3 (2.5)</td><td align="center" rowspan="1" colspan="1">2 (3.20)</td><td align="center" rowspan="1" colspan="1">1 (1.80)</td><td align="center" rowspan="1" colspan="1">1.000*</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;amputation</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mortality in</td><td align="center" rowspan="1" colspan="1">2 (1.7)</td><td align="center" rowspan="1" colspan="1">1 (1.60)</td><td align="center" rowspan="1" colspan="1">1 (1.80)</td><td align="center" rowspan="1" colspan="1">1.000*</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;all cause</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Bleeding</td><td align="center" rowspan="1" colspan="1">3 (2.5)</td><td align="center" rowspan="1" colspan="1">0 (0.00)</td><td align="center" rowspan="1" colspan="1">3 (5.30)</td><td align="center" rowspan="1" colspan="1">0.104*</td></tr></tbody></table><table-wrap-foot><fn><p>*Fisher&#x02019;s exact test. TLR: Target lesion revascularization.</p></fn></table-wrap-foot></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p>The Kaplan&#x02013;Meier survival curves for patients with restenosis.</p></caption><graphic xlink:href="CMJ-128-1563-g001"/></fig><p>In the sarpogrelate group, one patient discontinued the medication because of severe gastrointestinal discomfort. In clopidogrel group, three patients discontinued the medication because of gastrointestinal bleeding (1), skin rash (1) and liver dysfunction (1). The rate of study medication discontinuation because of side effects tended to be lower in the sarpogrelate group than in the clopidogrel group without significant difference (1.60% vs. 5.30%, <italic>P</italic> = 0.345). Bleeding rate was higher in the clopidogrel group than in sarpogrelate group, but there was no significant difference (5.30% vs. 0.00%, <italic>P</italic> = 0.104).</p></sec></sec><sec sec-type="discussion" id="sec1-4"><title>D<sc>ISCUSSION</sc></title><p>Our results demonstrate that there were no significant differences between sarpogrelate (plus aspirin) and clopidogrel (plus aspirin) with regard to effectiveness and safety after EVI of FP arterial lesions. However, comparing to the clopidogrel group, the sarpogrelate group has a lower restenosis rate, bleeding rate, and study medication discontinuation rate because of side effects. These data are consistent with our previous study and other published studies[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref10" ref-type="bibr">10</xref>] in animal models. Limited clinical studies[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref11" ref-type="bibr">11</xref>] showed sarpogrelate treatment reduces restenosis after coronary stenting comparing with ticlopidine. Unfortunately, there is no study which compares sarpogrelate with clopidogrel. Our study was a meaningful attempt to testify the underrated effectiveness and safety of sarpogrelate in clinical EVI cases. Clopidogrel and sarpogrelate differ significantly in the mechanism by which they antagonize platelet aggregation. Clopidogrel acts as an adenosine diphosphate receptor antagonist, whereas sarpogrelate not only acts as a selective 5-HT<sub>2A</sub> receptor antagonist but also inhibits smooth muscle proliferation.[<xref rid="ref12" ref-type="bibr">12</xref>] The clinical benefits of sarpogrelate are possibly due to the inhibition of 5-HT-induced platelet aggregation and vascular smooth muscle cell proliferation which is thought to be the major mechanisms of intimal hyperplasia and the chronic restenosis.</p><p>In the whole 120 cases with dual antiplatelet therapies in our study, the restenosis rate of 20% at 12 months after EVI of FP lesions was much lower than other studies[<xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>] of 41%&#x02013;54% with single aspirin therapy. And the bleeding rate and side effects of dual antiplatelet therapies were also acceptable. Dual antiplatelet therapies (sarpogrelate plus aspirin/clopidogrel plus aspirin) might play an important role in preventing restenosis after EVI of FP lesions.</p><p>One limitation of our study was a possible bias from confounding factors such as the state of run-off and the length of lesions although the randomized design of this study makes no significant difference between the two groups in basic characteristics. The other limitation is the limited cases in this study which might weaken the statistical validity. These questions, therefore, remain to be answered by future studies.</p><p>In conclusion, the present prospective randomized multicenter study suggests that aspirin plus sarpogrelate is a comparable antithrombotic regimen to aspirin plus clopidogrel after successful EVI of FP arterial lesions.</p></sec></body><back><fn-group><fn fn-type="edited-by"><p><bold>Edited by:</bold> Jian Gao</p></fn><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil.</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>R<sc>EFERENCES</sc></title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golledge</surname><given-names>J</given-names></name><name><surname>Ferguson</surname><given-names>K</given-names></name><name><surname>Ellis</surname><given-names>M</given-names></name><name><surname>Sabharwal</surname><given-names>T</given-names></name><name><surname>Davies</surname><given-names>AH</given-names></name><name><surname>Greenhalgh</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Outcome of femoropopliteal angioplasty</article-title><source>Ann Surg</source><year>1999</year><volume>229</volume><fpage>146</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">9923812</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schillinger</surname><given-names>M</given-names></name><name><surname>Sabeti</surname><given-names>S</given-names></name><name><surname>Loewe</surname><given-names>C</given-names></name><name><surname>Dick</surname><given-names>P</given-names></name><name><surname>Amighi</surname><given-names>J</given-names></name><name><surname>Mlekusch</surname><given-names>W</given-names></name><etal/></person-group><article-title>Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><fpage>1879</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">16672699</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laird</surname><given-names>JR</given-names></name><name><surname>Katzen</surname><given-names>BT</given-names></name><name><surname>Scheinert</surname><given-names>D</given-names></name><name><surname>Lammer</surname><given-names>J</given-names></name><name><surname>Carpenter</surname><given-names>J</given-names></name><name><surname>Buchbinder</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: Twelve-month results from the RESILIENT randomized trial</article-title><source>Circ Cardiovasc Interv</source><year>2010</year><volume>3</volume><fpage>267</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">20484101</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobel</surname><given-names>M</given-names></name><name><surname>Verhaeghe</surname><given-names>R</given-names></name></person-group><article-title>American College of Chest Physicians, American College of Chest Physicians. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8<sup>th</sup> Edition)</article-title><source>Chest</source><year>2008</year><volume>133</volume><fpage>815S</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">18574279</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>SK</given-names></name><name><surname>Zahradka</surname><given-names>P</given-names></name><name><surname>Chapman</surname><given-names>D</given-names></name><name><surname>Kumamoto</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>N</given-names></name><name><surname>Dhalla</surname><given-names>NS</given-names></name></person-group><article-title>Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate</article-title><source>J Pharmacol Exp Ther</source><year>1999</year><volume>290</volume><fpage>1475</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">10454527</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Pakala</surname><given-names>R</given-names></name><name><surname>Katagiri</surname><given-names>T</given-names></name><name><surname>Benedict</surname><given-names>CR</given-names></name></person-group><article-title>Angiotensin II and serotonin potentiate endothelin-1-induced vascular smooth muscle cell proliferation</article-title><source>J Hypertens</source><year>2001</year><volume>19</volume><fpage>731</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11330876</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>SK</given-names></name><name><surname>Del Rizzo</surname><given-names>DF</given-names></name><name><surname>Zahradka</surname><given-names>P</given-names></name><name><surname>Bhangu</surname><given-names>SK</given-names></name><name><surname>Werner</surname><given-names>JP</given-names></name><name><surname>Kumamoto</surname><given-names>H</given-names></name><etal/></person-group><article-title>Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: Implications for long-term graft patency</article-title><source>Ann Thorac Surg</source><year>2001</year><volume>71</volume><fpage>1856</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">11426759</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Origuchi</surname><given-names>N</given-names></name><name><surname>Shigematsu</surname><given-names>H</given-names></name><name><surname>Muto</surname><given-names>T</given-names></name></person-group><article-title>Anplag, a selective 5-HT2 receptor antagonist, reduces stenosis induced by balloon injury in the hypercholesterolaemic rabbit</article-title><source>Int Angiol</source><year>1997</year><volume>16</volume><fpage>204</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9405017</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name><name><surname>Ho</surname><given-names>M</given-names></name><name><surname>Tsukahara</surname><given-names>R</given-names></name><name><surname>Miyamoto</surname><given-names>A</given-names></name><name><surname>Miki</surname><given-names>O</given-names></name><etal/></person-group><article-title>Sarpogrelate treatment reduces restenosis after coronary stenting</article-title><source>Am Heart J</source><year>2003</year><volume>145</volume><fpage>E16</fpage><pub-id pub-id-type="pmid">12660685</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodama</surname><given-names>A</given-names></name><name><surname>Komori</surname><given-names>K</given-names></name><name><surname>Hattori</surname><given-names>K</given-names></name><name><surname>Yamanouchi</surname><given-names>D</given-names></name><name><surname>Kajikuri</surname><given-names>J</given-names></name><name><surname>Itoh</surname><given-names>T</given-names></name></person-group><article-title>Sarpogrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft</article-title><source>J Vasc Surg</source><year>2009</year><volume>49</volume><fpage>1272</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">19233592</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>A</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Shinozaki</surname><given-names>K</given-names></name><name><surname>Kotoku</surname><given-names>M</given-names></name><name><surname>Yano</surname><given-names>S</given-names></name><name><surname>Kadota</surname><given-names>J</given-names></name></person-group><article-title>Comparison of sarpogrelate and ticlopidine in bare metal coronary stent implantation</article-title><source>Int J Cardiol</source><year>2008</year><volume>126</volume><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">17507105</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saini</surname><given-names>HK</given-names></name><name><surname>Takeda</surname><given-names>N</given-names></name><name><surname>Goyal</surname><given-names>RK</given-names></name><name><surname>Kumamoto</surname><given-names>H</given-names></name><name><surname>Arneja</surname><given-names>AS</given-names></name><name><surname>Dhalla</surname><given-names>NS</given-names></name></person-group><article-title>Therapeutic potentials of sarpogrelate in cardiovascular disease</article-title><source>Cardiovasc Drug Rev</source><year>2004</year><volume>22</volume><fpage>27</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">14978517</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salapura</surname><given-names>V</given-names></name><name><surname>Blinc</surname><given-names>A</given-names></name><name><surname>Kozak</surname><given-names>M</given-names></name><name><surname>Jezovnik</surname><given-names>MK</given-names></name><name><surname>Pohar</surname><given-names>Perme M</given-names></name><name><surname>Berden</surname><given-names>P</given-names></name><etal/></person-group><article-title>Infrapopliteal run-off and the outcome of femoropopliteal percutaneous transluminal angioplasty</article-title><source>Vasa</source><year>2010</year><volume>39</volume><fpage>159</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">20464672</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shammas</surname><given-names>NW</given-names></name></person-group><article-title>An overview of optimal endovascular strategy in treating the femoropopliteal artery: Mechanical, biological, and procedural factors</article-title><source>Int J Angiol</source><year>2013</year><volume>22</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">24436577</pub-id></element-citation></ref></ref-list></back></article>